Health

Ascendion Recognized Among India's Top 50 Best Workplaces in Health & Wellness for the Third Consecutive Year

BENGALURU, India, April 30, 2026 /PRNewswire/ -- Ascendion, an AI-native software engineering company, has been recognized among the Top 50 ofIndia's Best Workplaces™ in Health & Wellness 2026: Companies That Care, marking its third consecutive year on the list.

2026-04-30 15:54 5259

Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases

SINGAPORE and TAIPEI, April 30, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage ...

2026-04-30 14:30 5180

New Classification System of Malocclusions Published in the Journal of Aligner Orthodontics (JAO) by Prof. Gang Shen's Team

SHANGHAI, April 30, 2026 /PRNewswire/ -- A seminal research paper titled "A New Classification System for Malocclusions with Facial Convexity"has been officially published in the 2026 Volume 1 issue of the Journal of Aligner Orthodontics (JAO). This article, authored by Professor Gang Shen and hi...

2026-04-30 13:33 4344

Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone in the company's transition fr...

2026-04-30 13:18 6057

Haier Biomedical Drives Global Leap of Life Science Infrastructure: International Business Hits Record High for 36% of Annual Revenue in 2025

AI-powered growth surges as Haier Biomedical scales from product coverage to premium brand leadership, building a global life science tools and intelligent productivity platform QINGDAO, China, April 30, 2026 /PRNewswire/ -- Haier Biomedical (688139.SH), a global leader in life sciences and medi...

2026-04-30 12:35 4499

2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

SHANGHAI, April 30, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be ...

2026-04-30 12:26 4635

D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types

Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes include: * 2L+ KRAS G12Ci–naïve NSCLC: ORR of 58.8%, mPFS of 12.2 months * 2L+ colorectal cancer (CRC): ORR of 46.9%, mPFS of 9.5 months ...

2026-04-30 11:20 4973

CMEF 2026 wraps up in Shanghai: a global stage for medical breakthroughs and future trends

SHANGHAI, April 30, 2026 /PRNewswire/ -- The 93rd China International Medical Equipment Fair (CMEF), together with its concurrent industry events, has successfully concluded on April 12 at the National Exhibition and Convention Center (Shanghai) after four days of exhibitions and exchanges. Under...

2026-04-30 10:26 4028

Taimei Technology Debuts at BioKorea 2026, Showcasing AI-Powered Clinical Research Solutions

SEOUL, South Korea, April 30, 2026 /PRNewswire/ -- Taimei Technology, a leading AI-driven drug clinical development platform, made its first public appearance in South Korea at BioKorea 2026, drawing significant attention with its advanced AI-powered clinical research technology solutions. Headq...

2026-04-30 10:00 3626

Classys Emerges as a Global Leader in Medical Aesthetics Beyond K-Beauty, Highlighting 45% Growth, 50%+ Margins, and Recurring Revenue Model

– Operations in 80+ countries with over 45,000 installed platforms and 66% international revenue mix – Consumables account for 46% of revenue, with more than 5.5 million HIFU procedures performed annually worldwide – Accelerating growth through two strategic M&A transactions over the past two yea...

2026-04-30 09:25 4311

ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies

TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collaboration with SeromYx Systems, specializing in advanced immunology technologies. The partne...

2026-04-30 08:30 5008

Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions

HONG KONG, April 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA's) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentat...

2026-04-30 08:10 4429

ACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidates

TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, announces its collaboration with Carterra, a company focused on innovative technologies designed to accelerate the discovery...

2026-04-30 08:00 4052

Frost & Sullivan Institute Announces Visionary Leadership Best Practices Recognition and This Year's Honorees

SAN ANTONIO, April 30, 2026 /PRNewswire/ -- The Frost & Sullivan Institute (FSI) is pleased to unveil this year's recipients of the Visionary Leadership Best Practices Recognition. These individuals exemplify purpose-driven leadership, bold innovation, and measurable impact aligned with FSI's mis...

2026-04-30 07:00 2677

OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

* TLX597-Tx is a PSMA[1]-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. * OPTIMAL-PSMA[2] initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification....

2026-04-30 05:00 5333

Infinitus Presents Human Evidence-Based Research Findings at FFC 2026

GUANGZHOU, China, April 30, 2026 /PRNewswire/ -- Ma Jun, Vice President and Chief Science Innovation Officer of Infinitus (China) Company Ltd., was invited to attend the Functional Food Conference 2026 (FFC 2026), held recently in Hangzhou, Zhejiang Province, where he delivered a keynote presenta...

2026-04-30 02:14 3968

New study demonstrates up to 73% reduction in genome analysis errors using AI-trained models versus standard approaches

SAN JOSE, Calif., April 29, 2026 /PRNewswire/ -- Complete Genomics , a U.S.-based leader in genomic sequencing technologies, todayannounced results demonstrating that AI-trained variant calling mode...

2026-04-29 23:02 5343

Navinci launches Omni kit - the next generation of spatial interactomics

UPPSALA, Sweden, April 29, 2026 /PRNewswire/ -- Navinci today announces the launch ofOmni, breakthrough fully customized kits designed to transform how scientists study protein function directly in tissue. Omni provides cutting-edge spatial interactomics capabilities, enabling researchers to map ...

2026-04-29 22:32 4005

WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access

* Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation * Enhancing governance transparency and effectiveness to create long-term value for all stakeholders * Empowering employees and fostering shared value ...

2026-04-29 20:30 4453

Vivacta Bio Closed Series A and Series A+ Financing of Over US$50 Million

Backed by Decheng Capital, Loyal Valley Capital, OrbiMed, and Other Renowned Investors SHANGHAI, April 29, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta" or "Vivacta Bio"), an innovative biotechnology company focused on revolutionizing in vivo CAR-T therapies, announc...

2026-04-29 20:15 2995
1 ... 18192021222324 ... 873